Data as of Sep 13, 2026. Both funds on the fields they both publish, from the same sources.
EWY vs XBI: how they differ
EWY and XBI hold 0% of their weight in the same names, and EWY returned more over the year.
iShares MSCI South Korea ETF and State Street(R) SPDR(R) S&P(R) Biotech ETF.
What they hold in common
By the books each fund has filed, EWY and XBI hold 0% of their money in the same securities at the same weight.
| Only in EWY | Only in XBI |
|---|---|
| SK HYNIX 24.02% | MODERNA INC 2.87% |
| SAMSUNG ELECTRONICS LTD 22.13% | TWIST BIOSCIENCE CORP 1.81% |
| SK SQUARE 3.01% | HALOZYME THERAPEUTICS INC 1.47% |
| KRW CASH 2.49% | NATERA INC 1.46% |
| SAMSUNG ELECTRO MECHANICS LTD 2.46% | KYMERA THERAPEUTICS INC 1.45% |
| KB FINANCIAL GROUP 1.92% | TRAVERE THERAPEUTICS INC 1.40% |
| HYUNDAI MOTOR 1.60% | ROIVANT SCIENCES LTD 1.39% |
| SHINHAN FINANCIAL GROUP 1.57% | ORUKA THERAPEUTICS INC 1.38% |
Weight overlap is an ETFIQ calculation: for every security both funds hold, the smaller of the two weights, summed. Above 50%, holding both is close to holding one of them twice. Holdings dated Sep 10, 2026.
| EWY iShares MSCI South Korea ETF | XBI State Street(R) SPDR(R) S&P(R) Biotech ETF | |
|---|---|---|
| Where it sits | Core index fund | Core index fund |
| Issuer | iShares | State Street |
| What it is | MSCI South Korea | SPDR S&P Biotech |
| Total return, 1 year | +147.9% | +64.0% |
| S&P 500 over the same days | +17.5% | +17.5% |
| Gap to the S&P 500 | +130.4 pts | +46.5 pts |
| Expense ratio | 0.59% | 0.35% |
| Already in the S&P 500 | 0.0% | 8.5% |
| Holdings | 80 | 154 |
EWY in plain words
EWY is an index equity fund tracking the MSCI South Korea. Over the year to Sep 11, 2026 it returned +147.9% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.59% a year. By its holdings filed for Sep 10, 2026, 0% of the fund by weight is stocks the S&P 500 also holds, across 80 positions, with the top ten at 61.9%. It sat 13.9% below its high of Jun 18, 2026 on Sep 11, 2026.
XBI in plain words
XBI is an index equity fund tracking the SPDR S&P Biotech. Over the year to Sep 11, 2026 it returned +64.0% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.35% a year. By its holdings filed for Sep 10, 2026, 8% of the fund by weight is stocks the S&P 500 also holds, across 154 positions, with the top ten at 15.9%. It sat 9.6% below its high of Feb 8, 2021 on Sep 11, 2026.
Questions people ask
- Which returned more over the last year, EWY or XBI?
- In the year to Sep 13, 2026, with distributions reinvested, EWY returned +147.9% and XBI returned +64.0%, so EWY returned more. One year is one year; the longer windows are in the table.
- Which is cheaper, EWY or XBI?
- EWY charges 0.59% a year and XBI charges 0.35%, so XBI is cheaper. Fees come from each fund's prospectus.
- How much do EWY and XBI overlap with the S&P 500?
- By their latest filed holdings, 0% of EWY and 8% of XBI by weight is stocks the S&P 500 already holds. Between the two funds, 0% of their books are the same securities at the same weight.
Other comparisons
Where to next
Where these figures came from
ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.
Cite this page. ETFIQ, EWY against XBI, data as of Sep 13, 2026. https://etfiq.com/compare/any/ewy-vs-xbi Free to use with attribution; the underlying files are at Open data.
A comparison is not a recommendation. Standards and sources